Zymeworks BC Inc (NASDAQ: ZYME) kicked off on Monday, down -4.28% from the previous trading day, before settling in for the closing price of $26.62. Over the past 52 weeks, ZYME has traded in a range of $9.03-$28.49.
Annual sales at Healthcare sector company grew by 15.81% over the past five years. While this was happening, its average annual earnings per share was recorded 40.06%. With a float of $72.86 million, this company’s outstanding shares have now reached $75.14 million.
Zymeworks BC Inc (ZYME) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Zymeworks BC Inc is 3.38%, while institutional ownership is 99.56%. The most recent insider transaction that took place on Jan 05 ’26, was worth 264,471. In this transaction EVP & Chief Medical Officer of this company sold 10,538 shares at a rate of $25.10, taking the stock ownership to the 18,352 shares. Before that another transaction happened on Jan 05 ’26, when Company’s Chair & CEO sold 54,343 for $25.10, making the entire transaction worth $1,363,841. This insider now owns 158,286 shares in total.
Zymeworks BC Inc (ZYME) Latest Financial update
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.31 earnings per share (EPS), lower than consensus estimate (set at -0.09) by -0.22. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 40.06% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 53.07% during the next five years compared to 15.81% growth over the previous five years of trading.
Zymeworks BC Inc (NASDAQ: ZYME) Trading Performance Indicators
Take a look at Zymeworks BC Inc’s (ZYME) current performance indicators. Last quarter, stock had a quick ratio of 6.94. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.85, a number that is poised to hit -0.47 in the next quarter and is forecasted to reach 0.57 in one year’s time.
Technical Analysis of Zymeworks BC Inc (ZYME)
Zymeworks BC Inc (NASDAQ: ZYME) saw its 5-day average volume 0.77 million, a negative change from its year-to-date volume of 1.12 million. As of the previous 9 days, the stock’s Stochastic %D was 33.87%.
During the past 100 days, Zymeworks BC Inc’s (ZYME) raw stochastic average was set at 80.50%, which indicates a significant increase from 26.57% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.07 in the past 14 days, which was higher than the 0.90 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $23.33, while its 200-day Moving Average is $16.02. Nevertheless, the first resistance level for the watch stands at $26.88 in the near term. At $28.27, the stock is likely to face the second major resistance level. The third major resistance level sits at $29.42. If the price goes on to break the first support level at $24.34, it is likely to go to the next support level at $23.19. The third support level lies at $21.80 if the price breaches the second support level.
Zymeworks BC Inc (NASDAQ: ZYME) Key Stats
The company with the Market Capitalisation of 1.92 billion has total of 74,837K Shares Outstanding. Its annual sales at the moment are 76,300 K in contrast with the sum of -122,700 K annual income. Company’s last quarter sales were recorded 27,610 K and last quarter income was -19,600 K.
